Nadja E. Schoemaker

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin

Nadja E. Schoemaker, Charlotte van Kesteren, Hilde Rosing et al. · British Journal of Cancer · 2002 · 119 citations · Full text

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

Nadja E. Schoemaker, I. E. L. M. Kuppens, Vladimir Moiseyenko et al. · British Journal of Cancer · 2004 · 34 citations · Full text

Urinary and fecal excretion of topotecan in patients with malignant solid tumours

Virginie M.M. Herben, Nadja E. Schoemaker, Hilde Rosing et al. · Cancer Chemotherapy and Pharmacology · 2002 · 33 citations

Fecal Excretion, Malignant Solid Tumours, Surgical Oncology +8

Phase I study of an oral formulation of irinotecan administered daily for 14�days every 3�weeks in patients with advanced solid tumours

Nadja E. Schoemaker, I. E. L. M. Kuppens, W.W. ten Bokkel Huinink et al. · Cancer Chemotherapy and Pharmacology · 2004 · 29 citations

Oncology, Pharmacology, Advanced Solid Tumours +8

High-Performance Liquid Chromatographic Analysis of the Anticancer Drug Irinotecan (CPT-11) and Its Active Metabolite SN-38 in Human Plasma

Nadja E. Schoemaker, Hilde Rosing, S Jansen et al. · Therapeutic Drug Monitoring · 2003 · 25 citations

Pharmaceutical Science, Pharmacotherapy, Medicinal Chemistry +23